Shares of Agios Pharmaceuticals plummeted in after-hours trading on Thursday after the company said that it was ceasing development of an anemia treatment due to a safety issue.
Cambridge-based Agios (Nasdaq: AGIO) said that it will stop developing the molecule, AG-519, which is designed to treat a rare form of anemia called pyruvate kinase deficiency. One healthy volunteer in a Phase 1 previously reported liver toxicity, prompting the FDA to place a clinical hold on the molecule. Agios said in…
Shares of Agios Pharmaceuticals plummeted in after-hours trading on Thursday after the company said that it was ceasing development of an anemia treatment due to a safety issue.
Cambridge-based Agios (Nasdaq: AGIO) said that it will stop developing the molecule, AG-519, which is designed to treat a rare form of anemia called pyruvate kinase deficiency. One healthy volunteer in a Phase 1 previously reported liver toxicity, prompting the FDA to place a clinical hold on the molecule. Agios said in…